Browse the evidence

Financial strain is independently associated with decreased subjective sleep quality and lower sleep efficiency in midlife women, regardless of race.

If you are experiencing financial stress, expect your sleep to suffer. This is not a failure of willpower but a physiological response to stress. Prioritize stress management techniques alongside sleep hygiene, as the economic pressure itself is a direct disruptor of sleep efficiency.

African American midlife women exhibit worse sleep outcomes, including decreased slow wave sleep and increased cortical hyperarousal, compared to Caucasian women, independent of socioeconomic status.

African American women may face inherent physiological challenges in achieving deep sleep (slow wave sleep) and maintaining sleep continuity compared to Caucasian women. This is not a personal failing but a documented physiological difference that may require tailored sleep strategies and stress management.

In women with visceral obesity, skeletal muscle insulin resistance is caused by a diminished capacity for postabsorptive free fatty acid (FFA) utilization, rather than by glucose-FFA substrate competition.

For women with high visceral fat, insulin resistance is linked to their muscles' inability to efficiently use fat for energy when fasting, not necessarily to high fat intake causing competition with glucose. Improving the muscle's capacity to oxidize fat (e.g., through exercise which increases mitochondrial enzymes like CPT and citrate synthase) may be a key target for improving insulin sensitivity.

Aging causes a redistribution of lipids from subcutaneous to visceral adipose tissue, leading to ectopic lipid storage, insulin resistance, and chronic low-grade systemic inflammation.

As you age, your body naturally shifts fat storage from under the skin to around your organs, which increases health risks. This shift is driven by hormonal changes and reduced activity of brown fat. While you can't stop aging, you can counteract these effects through regular exercise, weight management, and potentially medical interventions that improve insulin sensitivity, helping to maintain metabolic health and quality of life.

Aging is associated with an increase in pro-inflammatory adipokines and a decline in anti-inflammatory adipokines, contributing to a chronic state of low-grade systemic inflammation known as 'inflammaging'.

As you age, your fat cells release more inflammatory signals and fewer protective ones, leading to chronic low-grade inflammation. This 'inflammaging' increases the risk of diseases like diabetes and heart disease. Managing weight and staying active can help modulate these inflammatory signals.

Obesity, insulin resistance, and type 2 diabetes are pathological conditions associated with exaggerated and prolonged postprandial lipemia, characterized by delayed clearance of triacylglycerol-rich lipoproteins (TRL).

If you have obesity, insulin resistance, or type 2 diabetes, your body may struggle to clear fat from your blood after meals, leading to higher and longer-lasting triglyceride levels. This delayed clearance is a significant risk factor for heart disease, even if your fasting cholesterol looks okay. Managing these conditions through lifestyle and medication can help improve postprandial lipid clearance.

Obesity increases the risk of post-menopausal breast cancer primarily through increased bioavailability of oestrogens due to adipose tissue aromatization and reduced sex hormone-binding globulin (SHBG).

For post-menopausal women, maintaining a healthy weight is crucial for reducing breast cancer risk. This risk is driven by higher levels of bioavailable oestrogens. If you are not using hormone replacement therapy, weight management is a key protective factor.

Abdominal obesity is a significant risk factor for endometrial cancer, with risk increasing in a dose-dependent manner with weight gain, largely mediated by 'unopposed estrogen' from increased bioavailable oestrogens and low progesterone.

Maintaining a healthy weight is one of the most effective ways to reduce endometrial cancer risk. This risk is driven by hormonal imbalances, specifically high oestrogen and low progesterone. Weight loss, especially reducing abdominal fat, can significantly lower this risk.

Mitochondrial dysfunction is a necessary driver of the Senescence-Associated Secretory Phenotype (SASP), as evidenced by the elimination of SASP in cells devoid of mitochondria, while irreversible cell cycle arrest persists.

Aging and age-related inflammation are driven by dysfunctional mitochondria producing the SASP. Interventions that target mitochondrial health (e.g., senolytics, senostatics like rapamycin or metformin) may reduce this inflammatory burden. Focus on strategies that support mitochondrial quality control, such as exercise and metabolic health, rather than just energy output.

Exogenous ghrelin infusion suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans in a dose-dependent manner.

This research indicates that higher levels of the hormone ghrelin directly reduce the body's ability to secrete insulin in response to glucose, leading to worse glucose tolerance. For healthy individuals, this suggests that conditions or interventions that significantly elevate ghrelin (like prolonged fasting or specific pharmacological agents) might impair glucose handling. It does not suggest using ghrelin as a treatment, but rather highlights it as a factor to consider in metabolic health.

Loss of Bardet-Biedl syndrome (BBS) proteins causes leptin resistance and obesity by disrupting the physical interaction between BBS1 and the leptin receptor (LepRb), leading to defective intracellular trafficking and attenuated hypothalamic signaling.

This research identifies a specific biological mechanism where genetic defects prevent the brain from properly processing the 'fullness' signal (leptin) from fat cells. For individuals with Bardet-Biedl Syndrome or similar genetic variants affecting ciliary function, standard weight loss advice may fail because the body's internal signaling hardware is broken, not just the caloric balance. Future treatments may need to target the trafficking of the leptin receptor itself rather than just focusing on calorie intake.

Following an oral glucose load, skeletal muscle oxidation is the predominant metabolic fate of the glucose taken up by muscle, whereas glycogen storage accounts for less than 10% of the total oral load.

When you eat carbohydrates, your muscles primarily burn them for energy (oxidation) rather than storing them as glycogen. Only a small fraction (<10% of the total load) is stored in muscle. This challenges the common assumption that muscle is the main storage site for post-meal glucose.

PPARg is the master regulator of adipocyte differentiation; its deletion prevents fat cell development, while its activation is sufficient to induce adipogenesis in non-adipocyte cell types.

PPARg is the genetic switch for fat cell creation. Drugs like thiazolidinediones target this receptor to treat diabetes, highlighting its central role in metabolic health and fat storage.

Obstructive sleep apnoea (OSA) contributes to the development of insulin resistance and elevated inflammatory cytokines (IL-6, TNF-alpha) independently of obesity, with visceral fat being the primary anatomical driver.

If you have sleep apnoea, treating the breathing obstruction (e.g., with CPAP) is important, but it does not automatically fix your metabolic health. You must actively manage insulin sensitivity through diet and exercise, as OSA independently drives inflammation and insulin resistance regardless of your weight.

Metabolic syndrome (MetS) is independently associated with a higher risk of major cardiovascular events, cardiovascular mortality, and all-cause mortality, advancing the onset of these risks by approximately 3.2 years.

Having metabolic syndrome significantly increases your risk of heart attack, stroke, and early death, advancing the onset of these risks by over 3 years. However, managing individual components like high blood pressure, high triglycerides, or low HDL cholesterol is just as effective for risk reduction as treating the syndrome as a whole unit. Focus on controlling these specific metrics.

Metabolic syndrome is NOT associated with a higher risk of myocardial infarction or stroke, although individual components like elevated blood pressure, reduced HDL, and elevated triglycerides are.

Having metabolic syndrome does not necessarily increase your risk of heart attack or stroke, but managing individual components like high blood pressure, low HDL cholesterol, and high triglycerides does reduce this risk. Focus on controlling these specific markers.

Elevated tissue levels of specific ceramide species (C16:0 and C18:0) directly cause insulin resistance and metabolic dysfunction by inhibiting Akt/PKB signaling and mitochondrial efficiency.

High levels of specific fats called ceramides (C16:0 and C18:0) block your body's ability to use insulin, leading to high blood sugar and metabolic disease. While not all fats are bad, these specific ones are key drivers of insulin resistance. Managing overall metabolic health involves addressing these specific lipid accumulations, often through lifestyle changes that improve insulin sensitivity.

Perilipin phosphorylation by PKA is not required for Hormone-sensitive Lipase (HSL) translocation to lipid droplets, but is strictly required for the lipolytic activity of HSL once it is associated with the lipid droplet.

This research clarifies that the body's fat-burning machinery (HSL) can physically reach fat stores without the specific hormonal 'permission' (phosphorylation) previously thought necessary. However, without that hormonal signal, the fat is not actually broken down. This implies that while the machinery is present, the actual release of fatty acids depends on the hormonal state (e.g., stress, fasting, exercise) triggering the final catalytic step, not just the movement of the enzyme.

Prolonged TNF-α antagonism via etanercept improves fasting glucose and increases the proportion of high molecular weight (HMW) adiponectin in obese subjects with metabolic syndrome.

For obese individuals with metabolic syndrome, blocking TNF-α using etanercept can lower fasting glucose and improve the beneficial ratio of high molecular weight adiponectin. This is not a standard weight-loss treatment due to infection risks, but it may be a beneficial side effect for patients already treating autoimmune diseases like rheumatoid arthritis.

TNF-α antagonism with etanercept increases the ratio of high molecular weight (HMW) adiponectin to total adiponectin without changing total adiponectin levels or body composition.

Etanercept improves metabolic health by shifting adiponectin toward its most active form (HMW), rather than just increasing total amounts. This suggests TNF-α blockade helps the body utilize existing adiponectin more effectively.

Body fatness is regulated by an active biological feedback system (set point) involving signals like leptin that defend a target level of adiposity by modulating intake and expenditure.

Understand that your body has a biological 'thermostat' for fat. When you lose weight, your body actively fights to regain it by increasing hunger and decreasing energy expenditure. This is a normal biological response, not a personal failure. Successful long-term management requires strategies that account for this biological resistance, such as gradual changes and focusing on sustainable habits rather than rapid loss.

Gastric bypass surgery increases postprandial PYY levels, which contributes to reduced food intake and weight loss.

Bariatric surgery works partly by changing how your gut hormones signal fullness. After surgery, your body releases more PYY, which helps you feel full faster and stay full longer, contributing to sustained weight loss beyond just having a smaller stomach.

Serotonin 2C receptors (5-HT2CRs) expressed by POMC neurons mediate the anorexigenic effects of serotonin and drugs like lorcaserin.

Drugs like lorcaserin work by targeting serotonin receptors on specific brain neurons to reduce appetite.

Moderate alcohol consumption increases HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II, rather than by altering their fractional catabolic rate.

If you drink alcohol moderately, it may raise your HDL cholesterol levels by speeding up the production and transport of key proteins (apoA-I and apoA-II). This effect is dose-dependent, meaning more alcohol leads to a greater increase, up to a point. However, this does not necessarily mean heavy drinking is beneficial, as other health risks exist.